An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.
Status:
Terminated
Trial end date:
2021-06-18
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, open-label, single arm, Long Term Extension (LTE) safety,
tolerability and efficacy study of filgotinib in subjects with moderately to severely active
PsA. It is estimated that approximately 105 subjects will be rolled-over after they have
completed the 16 weeks of double-blind treatment in core study GLPG0634-CL-224. Subjects will
be administered filgotinib in this study until filgotinib is registered for PsA or until Week
304, whichever occurs first. The LTE study is concluded with a follow-up visit approximately
4 weeks after the last intake of study treatment.